Osaka Keisatsu Hospital

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Aortic stenosis2 trials
• Gastric and oesophageal cancer2 trials
• Aortic aneurysm1 trial
• Atrial fibrillation1 trial
• COPD1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Lupus (SLE)1 trial
• Peripheral artery disease1 trial
• Stroke1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Recruiting8 trials
• Active, not recruiting3 trials

Lead sponsor

• Eli Lilly and Company3 trials
• Medtronic Cardiovascular2 trials
• Abbott Medical Devices1 trial
• BeOne Medicines1 trial
• Biogen1 trial
• and 3 more

Running trials

• Recruiting

  A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

  NCT07733180· Phase 2· BeOne Medicines· Source

  Contact: Study Director

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

  Contact: Suguru Yamamoto (principal investigator)

• Recruiting

  Pemafibrate for Symptomatic ICAS RCT

  NCT07562178· Tokyo Women's Medical University· Source

  Contact: Yasutaka Murakami

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

  Contact: Osamu Iida (principal investigator)

• Recruiting

  Navitor Japan Study

  NCT07193888· Abbott Medical Devices· Source

  Contact: Yasuhiro Ichibori

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Masanori Miyazaki (principal investigator)

• Active, not recruiting

  Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia

  NCT06686485· Boston Scientific Corporation· Source

• Recruiting

  A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

  NCT06532006· Phase 3· Shanghai Henlius Biotech· Source

  Contact: Ying Li

• Recruiting

  Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

  NCT05378347· Medtronic Cardiovascular· Source

  Contact: Toru Kuratani (principal investigator)

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

• Active, not recruiting

  Evolut™ EXPAND TAVR II Pivotal Trial

  NCT05149755· Medtronic Cardiovascular· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer2 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• COPD1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Peripheral artery disease1 recruiting
• Stroke1 recruiting